Portfolio (Current & Past)
Payment Data Systems, Inc. (NASDAQ: PYDS)
Payment Data Systems is an integrated payment solutions provider to merchants and billers. The organization provides an extensive set of products to deliver world-class payment acceptance. Payment Data has solutions for merchants, billers, banks, service bureaus and card issuers. The strength of the company is its ability to offer specifically tailored solutions for card issuance, payment acceptance and bill payments.
Actinium is developing two radioimmunotherapy (RIT) drugs based on its APIT drug delivery platform. Iomab-B is being developed for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT) in relapsed and refractory AML patients age of 55 or older. The company is currently preparing for Phase III trial with Iomab-B. Its other product is Actimab-A, an antibody-drug construct containing iodine-131 used in myeloconditioning for HSCT in various indications. Actimab-A consists of mAb lintuzumab and alpha-emitting radioisotope actinium-225 (Ac-225). In November 2014, the FDA granted Orphan Drug designation for Actimab-A.
ATNM is collaborating with Fred Hutchinson Cancer Research Center (FHCRC) and Memorial Sloan Kettering Cancer Center (MSKCC) on its various programs. It also has IP collaboration with AbbVie (NYSE:ABBV). FHCRC has deep expertise in bone marrow transplantation research, and has Dr. E. Donnall Thomas who received the 1990 Nobel Prize in physiology/medicine for work in this area.
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.
IsoRay Medical™ utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay’s Cesium-131 isotope has been used as primary treatment for prostate cancer in over 7,000 patients. As adjuvant radiation therapy, Cesium-131 is being employed in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.
Additionally, Cesium-131 is currently being used as monotherapy in the management of gynecologic recurrences and ocular melanomas Customized strands, meshes, and applicators are available bearing Cesium-131 sources, and the recently reintroduced GliaSite Radiation Therapy System is available for brachytherapy of the resection bed following surgical removal of gliomas and brain metastases.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated. ImmunoCellular’s goal is to become an industry-leading, independent, commercial-stage cancer immunotherapy company. We have a development pipeline of therapeutically important, commercially attractive product candidates, and a highly productive, proprietary cancer immunotherapy platform. These assets have the potential to transform the treatment of cancer, benefit patients and create value for our stakeholders.
iBio, Inc. develops pharmaceutical product applications using its iBio Technology platform; a platform that has proven to be more efficient and cost-effective than traditional systems. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, bacteria, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals.
Seafarer Exploration Corp. is a publicly traded underwater salvage and exploration company.
The principal business of the company is to engage in the archaeologically-sensitive exploration, documentation, research and recovery of historic shipwrecks with the objective of exploring and discovering Colonial-era shipwrecks for future generations to be able to appreciate and understand. Seafarer currently has two different wreck sites under permit with the State of Florida and one wreck site under contract with a private party and is working closely with the Florida Department of Historical Resources and the Florida Bureau of Archeological Research to research and document these, and additional, wreck sites.
View our disclaimer.